ClinicalTrials.gg
CompletedNCT04603924Updated May 15, 2025Results posted

Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

A Phase 2/3 interventional study of Niclosamide and Placebo in COVID-19, sponsored by NeuroBo Pharmaceuticals Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-15.

Sponsored by NeuroBo Pharmaceuticals Inc. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
823rd of 1,321
49 · median 91
Started
2020
with 817 others
Phase 2/3
70 of 1,859
1 open now
Registered
758th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 823rd largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 70 in phase 2/3, and was the 758th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

Study of ANA001 in Moderate and Severe COVID-19 Patients

Read the detailed description

This is a 2 part, Phase 2/3 multi-center, double blinded, placebo-controlled study to assess the safety, tolerability, and efficacy of oral niclosamide (ANA001) in moderate and severe hospitalized COVID-19 patients compared to placebo.

03

Conditions studied

  • COVID-19

Keywords

  • Corona Virus Disease (COVID-19)
  • Niclosamide
  • Antiviral
  • Immunomodulator
  • Oral Niclosamide
  • Infection
  • Acute Respiratory Distress Syndrome (ARDS)
  • Cytokine dysregulation
  • Virus
  • Viral
  • anthelmintic
  • anti-inflammatory
  • bronchodilator
  • antineoplastic
  • ANA001
  • Moderate COVID-19
  • ARDS
  • Acute Respiratory Distress Syndrome
  • Hospitalized COVID-19
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Provide written prior to performing study procedures
  2. Hospitalized.
  3. Male or female ≥18 years of age
  4. Positive for severe acute respiratory syndrome coronavirus 2
  5. Presence of symptoms of lower respiratory tract infection (LRTI) including at least 1 of the following: fever, cough, sore throat, malaise, headache, muscle pain, or more significant lower respiratory tract symptoms, including shortness of breath
  6. At least 1 of the following: respiratory rate (RR) ≥20 breaths per minute, room air oxygen saturation (SpO2) \<98%, requirement for supplemental oxygen, heart rate (HR) ≥90 beats per minute, or temperature >38.3°C
  7. Women of must agree to abstinent or use at least 1 form of not including hormonal contraception from the day of screening through Day 30

Key Exclusion Criteria:

  1. Hospitalized but no longer requires ongoing inpatient care (i.e., discharge is anticipated in ≤24 hours)
  2. Patient is not anticipated to survive >48 hours OR is under palliative care
  3. Evidence of critical illness, defined by at least 1 of the following:

    • Respiratory failure requiring at least 1 of the following:

      1. Endotracheal intubation and mechanical ventilation, oxygen delivered by high flow nasal cannula
      2. Noninvasive positive pressure ventilation (NIPVV), OR
      3. Extracorporeal membrane oxygenation (ECMO) or clinical diagnosis of respiratory failure
    • Shock (defined by systolic blood pressure (BP) \<90 mm Hg, or diastolic blood pressure (BP) \<60 mm Hg or requiring vasopressors), OR
    • Multi-organ dysfunction/failure
  4. Severe central nervous system (CNS) conditions
  5. Chronic kidney disease requiring dialysis
  6. Known allergy to the study drug or salicylate containing medications.
  7. Suspected and/or confirmed pregnancy or breastfeeding
  8. Current or planned participation in any other clinical trial of a treatment being developed under a US new drug (IND) or emergency use authorization (EUA).
  9. Patients receiving chemotherapeutic agents and/or immunomodulators (including monoclonal antibodies (Mabs) or plasma transfusions) for chronic disease conditions.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    ANA001

    Subjects in the ANA001 treatment arm will receive 1,000 mg (4 capsules; 250 mg each) by mouth twice per day for 7 consecutive days with a meal. If the participant requires mechanical ventilation over the course of the study, ANA001 may be administered via nasogastric (NG), percutaneous endoscopic gastrostomy (PEG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding.

    Drug: Niclosamide

  • Placebo comparator
    Matching Placebo

    Subjects in the comparator arm will receive matching placebo (hydroxypropylmethylcellulose (HPMC)) (4 capsules, by mouth twice a day) for the 7-day treatment duration.

    Drug: Placebo

Interventions

  • Niclosamide is an antihelmintic with in-vitro antiviral activity

    Also known as: ANA001

  • DrugPlacebo

    Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients

    Also known as: Matching Placebo to ANA001

06

What researchers measure

Primary outcomes

  1. Number of Subjects Experiencing TEAEs

    Incidence of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Randomization to Day 60

  2. Number of Subjects Experiencing TESAEs

    Incidence of Treatment Emergent Serious Adverse Events (TESAEs)

    Time frame: Randomization to Day 60

Secondary outcomes

  1. Median Time to Hospital Discharge

    Median time until patient is discharged from hospital. Discharge is defined as a score of 1 or 2 in the WHO Ordinal Scale for Clinical Improvement. This is a 9 point ordinal scale with 0 indicating "No clinical or virological evidence of infection" and 8 indicating "Death".

    Time frame: Randomization to Day 60

  2. Median Time to 2-point Improvement WHO Clinical Improvement Scale

    Median Time to 2-point Improvement in WHO Ordinal Scale for Clinical Improvement. This is a 9 point ordinal scale with 0 indicating "No clinical or virological evidence of infection" and 8 indicating "Death"

    Time frame: Randomization to Day 60

  3. Median Time to Resolution of COVID-19 Symptoms

    Median time (in days) to resolution of subjective symptoms assessed by the Investigator to be potentially due to COVID-19 including: fever, cough (productive or non-productive), sore throat, malaise, headache, muscle pain, gastrointestinal symptoms (i.e., nausea, vomiting, or diarrhea), shortness of breath (with or without exertion), and respiratory distress

    Time frame: Randomization to Day 60

  4. Median Time to Time-to-Viral Load Undetectable

    Median number of days to viral load undetectable by nasopharyngeal (NP) swab

    Time frame: Randomization to Day 60

  5. AUC 0-t (h*ng/mL)

    Area under the drug concentration (h\*ng/mL) (AUC) vs time curve on Days 1 and 2

    Time frame: Pre- dose (within 30mins prior to each dose) and 1, 4 and 8 hours after each dose.

  6. Cmax (ng/mL)

    Maximum post dose plasma drug concentration on \[Cmax (ng/mL)\] Days 1 and 2

    Time frame: Pre- dose (within 30mins prior to each dose) and 1, 4 and 8 hours after each dose.

  7. Tmax (h)

    Time to maximum post dose plasma drug concentration on \[Tmax (h)\] Days 1 and 2

    Time frame: Pre- dose (within 30mins prior to each dose) and 1, 4 and 8 hours after each dose.

07

Results

Posted May 15, 2025

Participant flow

Participant flow — Overall Study
MilestoneANA001Matching Placebo
Started2524
Subjects dosed2323
Completed1515
Not completed109
Withdrew: Not dosed21
Withdrew: Withdrawal by subject66
Withdrew: Adverse event22

Outcome measures

PrimaryNumber of Subjects Experiencing TEAEs

Incidence of Treatment Emergent Adverse Events (TEAEs)

Time frame:
Randomization to Day 60
Reported as:
Count of participants · Participants
Number of Subjects Experiencing TEAEs
ParticipantsANA001Matching Placebo
No. of Subjects with any TEAE1612
No. of Subjects with Mild (Grade 1) TEAEs92
No. of Subjects with Moderate (Grade 2) TEAEs54
No. of Subjects with Severe (Grade 3) TEAEs02
No. of Subjects with Life-Threatening (Grade 4) TEAEs01
No. of Subjects with Death (Grade 5) TEAEs23
PrimaryNumber of Subjects Experiencing TESAEs

Incidence of Treatment Emergent Serious Adverse Events (TESAEs)

Time frame:
Randomization to Day 60
Reported as:
Count of participants · Participants
Number of Subjects Experiencing TESAEs
ParticipantsANA001Matching Placebo
Number of Subjects Experiencing TESAEs36
SecondaryMedian Time to Hospital Discharge

Median time until patient is discharged from hospital. Discharge is defined as a score of 1 or 2 in the WHO Ordinal Scale for Clinical Improvement. This is a 9 point ordinal scale with 0 indicating "No clinical or virological evidence of infection" and 8 indicating "Death".

Time frame:
Randomization to Day 60
Reported as:
Median · Days
Median Time to Hospital Discharge
DaysANA001Matching Placebo
Median Time to Hospital Discharge6.03 (3.07 to 14.89)13.92 (5.85 to NA)
Statistical analysis
  • ANA001 vs Matching Placebo ·
SecondaryMedian Time to 2-point Improvement WHO Clinical Improvement Scale

Median Time to 2-point Improvement in WHO Ordinal Scale for Clinical Improvement. This is a 9 point ordinal scale with 0 indicating "No clinical or virological evidence of infection" and 8 indicating "Death"

Time frame:
Randomization to Day 60
Reported as:
Median · Days
Median Time to 2-point Improvement WHO Clinical Improvement Scale
DaysANA001Matching Placebo
Median Time to 2-point Improvement WHO Clinical Improvement Scale4.15 (2.98 to 6.96)13.91 (5.85 to NA)
Statistical analysis
  • ANA001 vs Matching Placebo ·
SecondaryMedian Time to Resolution of COVID-19 Symptoms

Median time (in days) to resolution of subjective symptoms assessed by the Investigator to be potentially due to COVID-19 including: fever, cough (productive or non-productive), sore throat, malaise, headache, muscle pain, gastrointestinal symptoms (i.e., nausea, vomiting, or diarrhea), shortness of breath (with or without exertion), and respiratory distress

Time frame:
Randomization to Day 60
Reported as:
Median · Days
Median Time to Resolution of COVID-19 Symptoms
DaysANA001Matching Placebo
Median Time to Resolution of COVID-19 Symptoms17 (9 to 36)16 (11 to 24)
SecondaryMedian Time to Time-to-Viral Load Undetectable

Median number of days to viral load undetectable by nasopharyngeal (NP) swab

Time frame:
Randomization to Day 60
Reported as:
Median · Days
Median Time to Time-to-Viral Load Undetectable
DaysANA001Matching Placebo
Median Time to Time-to-Viral Load Undetectable13.09 (2.87 to 27.04)13.1 (2.99 to 15.10)
SecondaryAUC 0-t (h*ng/mL)

Area under the drug concentration (h\*ng/mL) (AUC) vs time curve on Days 1 and 2

Time frame:
Pre- dose (within 30mins prior to each dose) and 1, 4 and 8 hours after each dose.
Reported as:
Mean · h*ng/mL
AUC 0-t (h*ng/mL)
h*ng/mLANA001
Day 1: AUC 0-t (h*ng/mL)1728.6 ± 1410.21
Day 2: AUC 0-t (h*ng/mL)2839.0 ± 1702.25
SecondaryCmax (ng/mL)

Maximum post dose plasma drug concentration on \[Cmax (ng/mL)\] Days 1 and 2

Time frame:
Pre- dose (within 30mins prior to each dose) and 1, 4 and 8 hours after each dose.
Reported as:
Mean · ng/mL
Cmax (ng/mL)
ng/mLANA001
Day 1: Cmax (ng/mL)348.06 ± 212.343
Day 2: Cmax (ng/mL)435.91 ± 204.059
SecondaryTmax (h)

Time to maximum post dose plasma drug concentration on \[Tmax (h)\] Days 1 and 2

Time frame:
Pre- dose (within 30mins prior to each dose) and 1, 4 and 8 hours after each dose.
Reported as:
Mean · (h)
Tmax (h)
(h)ANA001
Day 1: Tmax (h)4.884 ± 2.3139
Day 2: Tmax (h)3.983 ± 2.4002

Adverse events

Collected over TEAEs are any adverse events that emerge on or after first dosing and up to 28 days after last dose during follow-up.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ANA0012/22 (9.1%)3/22 (13.6%)16/22 (72.7%)
Matching Placebo3/23 (13%)6/23 (26.1%)12/23 (52.2%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventANA001Matching Placebo
Respiratory failureRespiratory, thoracic and mediastinal disorders1/224/23
Septic shockInfections and infestations1/223/23
SepsisInfections and infestations1/220/23
Subdural haematomaInjury, poisoning and procedural complications1/220/23
DizzinessNervous system disorders1/220/23
AnxietyPsychiatric disorders1/220/23
Renal tubular necrosisRenal and urinary disorders1/220/23
Deep vein thrombosisVascular disorders1/220/23
Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders0/221/23
HaemothoraxRespiratory, thoracic and mediastinal disorders0/221/23
Most frequent other events
Showing 10 of 71
Most frequent other events
EventANA001Matching Placebo
InsomniaPsychiatric disorders1/225/23
AnxietyPsychiatric disorders2/223/23
ConstipationGastrointestinal disorders1/223/23
NauseaGastrointestinal disorders2/221/23
DiarrhoeaGastrointestinal disorders2/220/23
HypocalcaemiaMetabolism and nutrition disorders2/221/23
HypokalaemiaMetabolism and nutrition disorders2/221/23
HyponatraemiaMetabolism and nutrition disorders2/221/23
FallInjury, poisoning and procedural complications2/220/23
HyperglycaemiaMetabolism and nutrition disorders1/222/23

Baseline characteristics

Age, Customized
Age, Customized(Participants)ANA001Matching PlaceboTotal
18 -<40 Years538
40-<65 Years131528
>/=65 Years7613
Sex: Female, Male
Sex: Female, Male(Participants)ANA001Matching PlaceboTotal
Female131023
Male121426
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ANA001Matching PlaceboTotal
Hispanic or Latino8412
Not Hispanic or Latino171835
Unknown or Not Reported022
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ANA001Matching PlaceboTotal
American Indian or Alaska Native011
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American347
White201838
More than one race101
Unknown or Not Reported112
Days from First COVID-19 Symptom to Randomisation
Days from First COVID-19 Symptom to Randomisation(Days)ANA001Matching PlaceboTotal
Mean7.6 ± 4.127.7 ± 3.537.7 ± 3.81
Baseline WHO Ordinal Scale for Clinical Improvement
Baseline WHO Ordinal Scale for Clinical Improvement(Participants)ANA001Matching PlaceboTotal
Baseline World Health Organisation (WHO) Ordinal Scale for Clinical Improvement= 4347
Baseline World Health Organisation (WHO) Ordinal Scale for Clinical Improvement = 5191736
Baseline World Health Organisation (WHO) Ordinal Scale for Clinical Improvement = 6123
Baseline World Health Organisation (WHO) Ordinal Scale for Clinical Improvement = Missing213
08

Study locations

8 sites
  • Helen Keller Hospital
    Sheffield, Alabama 35660, United States
  • University of California, Irvine
    Irvine, California 92697, United States
  • Baptist Health Research Institute
    Jacksonville, Florida 32207, United States
  • AdventHealth Tampa
    Tampa, Florida 33613, United States
  • University of Missouri Health Care
    Columbia, Missouri 65212, United States
  • Caroline Institute for Clinical Research
    Fayetteville, North Carolina 28303, United States
  • Memorial Hermann Memorial City Medical Center
    Houston, Texas 77024, United States
  • Providence Regional Medical Center Everett
    Everett, Washington 92801, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Feb 2022, 16 months.

Results were first posted in May 2025, 3 years 2 months after primary completion.

Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 16 months is above that.

Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2020
First posted
Oct 27, 2020
StartActual
Oct 7, 2020
Primary completionActual
Feb 16, 2022
CompletionActual
Feb 16, 2022
Results first posted
May 15, 2025
Last update
May 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04603924
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Oct 27, 2020
Start date
Oct 7, 2020
Primary completion
Feb 16, 2022
Completion
Feb 16, 2022
Results posted
May 15, 2025
Last update
May 15, 2025

Study contacts

Doug Rank, MD
study director · NeuroBo Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niclosamide

Start the discussion